

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#2  
PATENT  
7/10/01

jc997 U.S. PTO  
09/850370  
05/07/01

Applicants:	Louis Crocker, et al.	
Serial No.:	TO BE ASSIGNED	Case No.: 19892DB
Filed:	TO BE ASSIGNED	
For:	POLYMORPHIC FORM OF A TACHYKININ RECEPTOR ANTAGONIST	

Art Unit:

Unassigned

Examiner:

Unassigned

The Honorable Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

**EXPRESS MAIL CERTIFICATE**  
DATE OF DEPOSIT May 7, 2001  
EXPRESS MAIL NO. EL523908322US  
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS  
BEING DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS EXPRESS MAIL "POST OFFICE TO  
ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN  
AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER  
FOR PATENTS, WASHINGTON, D.C., 20231.  
MAILED BY [Signature]  
DATE May 7, 2001

Serial No.: To be assigned  
Case No.: 19892DB  
Page No.: 2

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention. In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.


Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the subject application.

Copies of the references that are cited on the attached form PTO-1449 were previously submitted to or cited by the Office in prior application U.S. Serial Number 09/458,168, filed December 9, 1999 (Merck Case No. 19892DA) which is a continuation of U.S. Serial Number 09/212,511, filed December 15, 1998 (Merck Case No. 19892), upon which the instant application relies for an earlier filing date under 35 U.S.C. § 120. Therefore, pursuant to 37 CFR § 1.98(d), copies of these references are not enclosed herewith.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By

  
J. Eric Thies  
Reg. No. 35,382  
Attorney for Applicant

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-3904

Date: May 7, 2001